BioCatalystWatch
SEPNWorkspace / SEPN / OverviewCompany library
Price
Market cap
Next catalystExpected Q1 2027SEP-479 — Phase 1 SAD/MAD in healthy adults · Phase 1 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

SEP-479

PTH1R

PreINDP1P2P3FilingApproved
Upcoming / outlook

SEP-204

TSHR

PreINDP2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

SEP-479

PTH1R

PreINDP1P2P3FilingApproved
Upcoming / outlook

SEP-204

TSHR

PreINDP2P3FilingApproved
Upcoming / outlook

Other pipelines

SEP-479

PTH1R

PreINDP1P2P3FilingApproved
incretin receptor program

GLP-1R × GIPR × GCGR

PreINDP1P2P3FilingApproved
PTH1R agonist program

PTH1R

PreINDP1P2P3FilingApproved

Partner / License out

GLP-1R × GIPR × GCGR

PreINDP1P2P3FilingApproved

History / paused

PTH1R × UGT1A1

PreINDP1P2P3FilingApproved

MRGPRX2

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

SEPN PR & News

SEPN SEC archive